PCP
TVTX icon

Proficio Capital Partners’s Travere Therapeutics TVTX Stock Holding History

Proficio Capital Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-393
Closed -$8K – 1433
2019
Q2 		$8K Buy
+393
New +$7.76K ﹤0.01% 1044

Other funds holding TVTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Proficio Capital Partners's TVTX Position: Q3 2019 in Review

Proficio Capital Partners sold out of Travere Therapeutics (TVTX) in Q3 2019, closing a stake of 393 shares — an estimated $8K sold.

Proficio Capital Partners first reported a position in TVTX in Q2 2019 and held it in 1 quarter. The position peaked at $8K in Q2 2019. 130 funds tracked by Wall St. Rank hold TVTX as of Q3 2019.

  • Proficio Capital Partners reported no remaining Travere Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Proficio Capital Partners sold 393 Travere Therapeutics shares in Q3 2019, an estimated $8K.
  • Proficio Capital Partners first reported a position in Travere Therapeutics in Q2 2019 and held it in 1 quarter.
  • Proficio Capital Partners's Travere Therapeutics position peaked at $8K in Q2 2019.
  • 130 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2019.

Based on Proficio Capital Partners's 13F filing for Q3 2019, filed 13 Nov 2019.